Roivant Sciences (NASDAQ:ROIV) Stock: Insider Richard Pulik Sells 125,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CFO Richard Pulik sold 125,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $41.20, for a total transaction of $5,150,000.00. Following the sale, the chief financial officer owned 269,681 shares in the company, valued at approximately $11,110,857.20. The trade was a 31.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Richard Pulik also recently made the following trade(s):

• On Wednesday, November 11th, Richard Pulik sold 175,000 shares of Roivant Sciences stock. The stock was sold at an average price of $41.85, for a total transaction of $7,323,750.00.

Roivant Sciences Stock Performance

Shares of ROIV traded down $1.86 during mid-day trading on Thursday, reaching $39.99. The stock had a trading volume of 8,744,046 shares, compared to its average volume of 8,291,942. The business has a fifty day moving average of $37.20 and a 200 day moving average of $32.16. Roivant Sciences Ltd. has a 12 month low of $19.96 and a 12 month high of $42.50.

Analyst Ratings Changes

ROIV has been the topic of a number of analyst reports. Wolfe Research cut shares of Roivant Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, October 12th. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. UBS Group set a $55.00 price target on Roivant Sciences in a report on Wednesday, September 9th. Guggenheim raised their price target on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Finally, Citigroup boosted their price objective on Roivant Sciences from $46.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $46.64.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. Meeder Advisory Services Inc. grew its holdings in Roivant Sciences by 15.3% during the 3rd quarter. Meeder Advisory Services Inc. now owns 8,899 shares of the company’s stock valued at $325,000 after buying an additional 1,182 shares in the last quarter. Benjamin Edwards Inc. increased its stake in Roivant Sciences by 79.8% in the 3rd quarter. Benjamin Edwards Inc. now owns 11,145 shares of the company’s stock worth $408,000 after acquiring an additional 4,947 shares during the last quarter. First Trust Advisors LP increased its stake in Roivant Sciences by 98.3% in the 3rd quarter. First Trust Advisors LP now owns 929,263 shares of the company’s stock worth $33,983,000 after acquiring an additional 460,640 shares during the last quarter. Resona Asset Management Co. Ltd. bought a new stake in Roivant Sciences in the 3rd quarter worth approximately $4,926,000. Finally, Private Advisor Group LLC raised its holdings in shares of Roivant Sciences by 103.4% during the 3rd quarter. Private Advisor Group LLC now owns 28,144 shares of the company’s stock worth $1,029,000 after acquiring an additional 14,304 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.